Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Innate Pharma is a European biotech specializing in the development of immunotherapeutics for various cancer types. Their most advanced projects focus on engaging and activating natural killer cells, ...
Innate Pharma SA IPHA announced that the FDA lifted the partial clinical hold placed on the lacutamab investigational new drug (IND) in October 2023. Innate Pharma’s lead proprietary program, ...
Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback